Argenx
ARGX
#456
Rank
A$78.11 B
Marketcap
A$1,249
Share price
3.37%
Change (1 day)
44.56%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): A$23.66

According to Argenx 's latest financial reports the company's current EPS (TTM) is A$22.57. In 2025 the company made an earnings per share (EPS) of A$30.09 an increase over its 2024 EPS that were of A$19.87.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$23.66-21.36%
2025A$30.0951.44%
2024A$19.87-369.77%
2023A-$7.37-60.46%
2022A-$18.6363.33%
2021A-$11.40-40.37%
2020A-$19.13183.47%
2019A-$6.75123.09%
2018A-$3.0254.93%
2017A-$1.9514.07%
2016A-$1.7113.05%
2015A-$1.51-36.34%
2014A-$2.38209.04%
2013A-$0.77-33.99%
2012A-$1.17185.59%
2011A-$0.41